Prevalence of Current and Past SARS-CoV-2 Infections among Police Employees in Poland, June–July 2020
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design and Participants
2.2. Measurements
2.2.1. RT-PCR Testing for Current SARS-CoV-2 Infection
2.2.2. Serological Tests for the Presence of Anti-SARS-CoV-2 IgM+IgA and IgG Antibodies
2.3. Study Questionnaire
2.3.1. Sample Size
2.3.2. Quantitative Variables
2.4. Statistical Analysis
2.5. Ethics Approval
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020, 395, 497–506. [Google Scholar] [CrossRef] [Green Version]
- US Food and Drug Administration, FAQs on Testing for SARS CoV-2. Available online: https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/faqs-testing-sars-cov-2 (accessed on 14 September 2020).
- Pollán, M.; Pérez-Gómez, B.; Pastor-Barriuso, R.; Oteo, J.; Hernán, M.A.; Pérez-Olmeda, M.; Sanmartín, J.L.; Fernández-García, A.; Cruz, I.; Fernández de Larrea, N.; et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): A nationwide, population-based seroepidemiological study. Lancet 2020, 396, 535–544. [Google Scholar] [CrossRef]
- Gudbjartsson, D.F.; Norddahl, G.L.; Melsted, P.; Gunnarsdottir, K.; Holm, H.; Eythorsson, E.; Arnthorsson, A.O.; Helgason, D.; Bjarnadottir, K.; Ingvarsson, R.F.; et al. Humoral immune response to SARS-CoV-2 in Iceland. New Engl. J. Med. 2020. [Google Scholar] [CrossRef] [PubMed]
- PulsBiznesu. (95% of Infected are Asymptomatic). Available online: https://www.pb.pl/pgg-975-proc-zakazonych-pracownikow-przechodzi-chorobe-bezobjawowo-993941 (accessed on 12 September 2020).
- Gujski, M.; Raciborski, F.; Jankowski, M.; Nowicka, P.M.; Rakocy, K.; Pinkas, J. Epidemiological Analysis of the First 1389 Cases of COVID-19 in Poland: A Preliminary Report. Med. Sci. Monit. 2020, 26, e924702. [Google Scholar] [PubMed]
- World Health Organization. Weekly Epidemiological Update, Coronavirus Disease 2019 (COVID-19) as of 21 September 2020. Available online: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200921-weekly-epi-update-6.pdf?sfvrsn=d9cf9496_6 (accessed on 14 September 2020).
- Raciborski, F.; Pinkas, J.; Jankowski, M.; Sierpiński, R.; Zgliczyński, W.S.; Szumowski, Ł.; Rakocy, K.; Wierzba, W.; Gujski, M. Dynamics of the coronavirus disease 2019 outbreak in Poland: An epidemiological analysis of the first 2 months of the epidemic. Pol. Arch. Intern. Med. 2020, 130, 615–621. [Google Scholar] [PubMed]
- Ministry of Health. Daily Up-Date on COVID-19, as of April 12, 2020. Available online: https://twitter.com/MZ_GOV_PL/status/1249354715940507649 (accessed on 14 September 2020).
- Ministry of Health. Daily Up-Date on COVID-19, as of September 6, 2020. Available online: https://twitter.com/MZ_GOV_PL/status/1302516889420062720 (accessed on 14 September 2020).
- World Health Organization. Laboratory Testing for Coronavirus Disease 2019 (COVID-19) in Suspected Human Cases. Available online: https://apps.who.int/iris/bitstream/handle/10665/331329/WHO-COVID-19-laboratory-2020.4-eng.pdf (accessed on 14 September 2020).
- World Health Organization. Survey Tool and Guidance. Rapid Simple, Flexible Behavioural Insights on COVID-19. Available online: https://www.euro.who.int/__data/assets/pdf_file/0007/436705/COVID-19-survey-tool-and-guidance.pdf (accessed on 14 September 2020).
- Główny Inspektorat Sanitarny (Chief Sanitary Inspectorate). Available online: https://www.gov.pl/web/gis (accessed on 14 September 2020).
- Vabret, N.; Britton, G.J.; Gruber, C.; Hegde, S.; Kim, J.; Kuksin, M.; Levantovsky, R.; Malle, L.; Moreira, A.; Park, M.D.; et al. Immunology of COVID-19: Current state of the science. Immunity 2020, 52, 910–941. [Google Scholar] [CrossRef] [PubMed]
- Sekine, T.; Perez-Potti, A.; Rivera-Ballesteros, O.; Strålin, K.; Gorin, J.B.; Olsson, A.; Llewellyn-Lacey, S.; Kamal, H.; Bogdanovic, G.; Muschiol, S.; et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 2020. [Google Scholar] [CrossRef] [PubMed]
- Burke, R.M.; Killerby, M.E.; Newton, S.; Ashworth, C.E.; Berns, A.L.; Brennan, S.; Bressler, J.M.; Bye, E.; Crawford, R.; Morano, L.H. Symptom Profiles of a Convenience Sample of Patients with COVID-19—United States, January-April 2020. MMWR Morb. Mortal. Wkly. Rep. 2020, 69, 904–908. [Google Scholar] [CrossRef]
- Li, L.; Sun, W.; Han, M.; Ying, Y.; Wang, Q. A Study on the Predictors of Disease Severity of COVID-19. Med. Sci. Monit. 2020, 26, e927167. [Google Scholar]
- Baj, J.; Karakuła-Juchnowicz, H.; Teresiński, G.; Buszewicz, G.; Ciesielka, M.; Sitarz, E.; Forma, A.; Karakuła, K.; Flieger, W.; Portincasa, P.; et al. COVID-19: Specific and Non-Specific Clinical Manifestations and Symptoms: The Current State of Knowledge. J. Clin. Med. 2020, 9, 1753. [Google Scholar] [CrossRef]
- Kohmer, N.; Westhaus, S.; Rühl, C.; Ciesek, S.; Rabenau, H.F. Clinical performance of SARS-CoV-2 IgG antibody tests and potential protective immunity. bioRxiv 2020. [Google Scholar] [CrossRef]
- Serology Taskforce. Status of the Validation of ELISA and Auto-Analyser Antibody Tests for SARS-CoV-2 Diagnostics: Considerations for Use. Available online: https://www.rivm.nl/sites/default/files/2020-07/Status%20validation%20ELISA%20and%20auto-analysers%202020715.pdf (accessed on 14 September 2020).
- Wechselberger, C.; Süßner, S.; Doppler, S.; Bernhard, D. Performance evaluation of serological assays to determine the immunoglobulin status in SARS-CoV-2 infected patients. J. Clin. Virol. 2020, 131, 104589. [Google Scholar] [CrossRef] [PubMed]
- Cobos, A.G.; de Frutos, S.G.; Garcia, D.D.; Lara, E.N.; Carrion, A.Y.; Garcia-Rodrigo, L.F.; Fraile Torres, A.M.; Cardeñoso Domingo, L. Evaluation of diagnostic accuracy of 10 serological assays for detection of SARS-CoV-2 antibodies. Res. Sq. 2020. [Google Scholar] [CrossRef]
- Jin, J.M.; Bai, P.; He, W.; Wu, F.; Liu, X.F.; Han, D.H.; Liu, S.; Yang, J.K. Gender differences in patients with COVID-19: Focus on severity and mortality. Front. Public Health 2020, 8, 152. [Google Scholar] [CrossRef]
- Riccardo, F.; Ajelli, M.; Andrianou, X.; Bella, A.; del Manso, M.; Fabiani, M.; Bellino, S.; Boros, S.; Urdiales, A.M.; Marziano, V.; et al. Epidemiological characteristics of COVID-19 cases in Italy and estimates of the reproductive numbers one month into the epidemic. medRxiv 2020. [Google Scholar] [CrossRef] [Green Version]
- Gilpin, D.F.; McGown, K.A.; Gallagher, K.; Bengoechea, J.; Dumigan, A.; Einarsson, G.; Elborn, J.S.; Tunneym, M.M. Electronic cigarette vapour increases virulence and inflammatory potential of respiratory pathogens. Respir. Res. 2019, 20, 267. [Google Scholar] [CrossRef]
- Gaiha, S.M.; Cheng, J.; Halpern-Felsher, B. Association between youth smoking, electronic cigarette use, and coronavirus disease 2019. J. Adolesc. Health 2020. [Google Scholar] [CrossRef]
- Fontanet, A.; Tondeur, L.; Madec, Y.; Grant, R.; Besombes, C.; Jolly, N.; Pellerin, S.F.; Ungeheuer, M.N.; Cailleau, I.; Kuhmel, L. Cluster of COVID-19 in northern France: A retrospective closed cohort study. medRxiv 2020. [Google Scholar] [CrossRef] [Green Version]
- Slot, E.; Hogema, B.M.; Reusken, C.B.E.M.; Reimerink, J.H.; Molier, M.; Karregat, J.H.M.; IJlst, J.; Novotný, V.M.J.; van Lier, R.A.W.; Zaaijer, H.L. Herd immunity is not a realistic exit strategy during a COVID-19 outbreak. Res. Sq. 2020. [Google Scholar] [CrossRef]
- Stringhini, S.; Wisniak, A.; Piumatti, G.; Azman, A.S.; Lauer, S.A.; Baysson, H.; De Ridder, D.; Petrovic, D.; Schrempft, S.; Marcus, K.; et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): A population-based study. Lancet 2020, 396, 313–319. [Google Scholar] [CrossRef]
- Valenti, L.; Bergna, A.; Pelusi, S.; Facciotti, F.; Lai, A.; Tarkowski, M.; Berzuini, A.; Caprioli, F.; Santoro, L.; Baselli, G.; et al. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 Milan outbreak. medRxiv 2020. [Google Scholar] [CrossRef]
Variable | Anti-SARS-CoV-2 IgM+IgA index | Anti-SARS-CoV-2 IgG index | |
---|---|---|---|
Mean | 4.4 | 3.1 | |
95%CI | LL | 4.3 | 3.0 |
UL | 4.5 | 3.2 | |
Median | 3.5 | 2.6 | |
Standard deviation (SD) | 3.6 | 2.7 | |
Minimum | 0.0 | 0.0 | |
Maximum | 43.5 | 44.8 | |
Range | 43.5 | 44.8 | |
Interquartile range | 2.8 | 1.6 | |
Percentiles | 5 | 1.3 | 1.1 |
10 | 1.6 | 1.4 | |
25 | 2.4 | 1.9 | |
50 | 3.5 | 2.6 | |
75 | 5.2 | 3.5 | |
90 | 7.6 | 4.6 | |
95 | 10.0 | 5.7 |
Anti-SARS-CoV-2 IgA + IgM Index | Anti-SARS-CoV-2 IgG Index | ||||
---|---|---|---|---|---|
Negative (<4) (n = 4196) | Equivocal (4–6) (n = 669) | Positive (>6) (n = 217) | Overall (n = 5082) * | ||
n (%) | n (%) | n (%) | n (%) | ||
Negative(<6) | 3506 (83.6) | 482 (72.0) | 148 (68.2) | 4136 (81.4) | |
Equivocal (6–8) | 371 (8.8) | 95 (14.2) | 30 (13.8) | 496 (9.8) | |
Positive (>8) | 319 (7.6) | 92 (13.8) | 39 (18.0) | 450 (8.9) |
Variables | Anti-SARS-CoV-2 IgM+IgA Index | SARS-CoV-2 IgG Index | ||||||
---|---|---|---|---|---|---|---|---|
OR 95% CI | OR 95% CI | |||||||
p | OR | Lower | Upper | p | OR | Lower | Upper | |
Gender (women) | 0.000 | 1.742 | 1.377 | 2.203 | 0.572 | 1.104 | 0.784 | 1.554 |
Age group (30–44 years) | 0.257 | 0.833 | 0.607 | 1.143 | 0.360 | 1.266 | 0.764 | 2.098 |
Age group (45–59 years) | 0.578 | 0.905 | 0.637 | 1.286 | 0.550 | 1.184 | 0.680 | 2.061 |
Age group (60 and more) | 0.243 | 0.617 | 0.275 | 1.386 | 0.005 | 3.309 | 1.442 | 7.595 |
Place of residence (town up to 20,000 residents) | 0.012 | 1.526 | 1.099 | 2.119 | 0.934 | 0.980 | 0.611 | 1.572 |
Place of residence (city between 20,000 and 500,000 residents) | 0.000 | 1.657 | 1.257 | 2.183 | 0.366 | 1.189 | 0.817 | 1.729 |
Place of residence (city above 500,000 residents) | 0.111 | 1.276 | 0.946 | 1.721 | 0.461 | 1.159 | 0.783 | 1.716 |
Living with one or more persons (yes) | 0.246 | 1.272 | 0.847 | 1.909 | 0.639 | 1.154 | 0.634 | 2.098 |
Presence of children aged 0–17 at home (daily) | 0.581 | 0.936 | 0.739 | 1.185 | 0.541 | 1.111 | 0.793 | 1.557 |
Presence of children aged 0–17 at home (occasionally) | 0.558 | 0.837 | 0.462 | 1.518 | 0.068 | 0.158 | 0.022 | 1.147 |
Police officer (yes) | 0.047 | 1.411 | 1.004 | 1.981 | 0.317 | 1.279 | 0.790 | 2.068 |
Type of employment (office-based) | 0.513 | 0.883 | 0.608 | 1.282 | 0.123 | 1.530 | 0.892 | 2.625 |
Type of employment (both office-based and fieldwork) | 0.502 | 0.903 | 0.670 | 1.216 | 0.367 | 1.230 | 0.784 | 1.929 |
Average number of contacts per person perday (<5 persons) | 0.123 | 2.119 | 0.815 | 5.510 | 0.791 | 1.311 | 0.177 | 9.679 |
Average number of contacts per person perday (5–9 persons) | 0.572 | 0.801 | 0.371 | 1.729 | 0.540 | 1.593 | 0.359 | 7.072 |
Average number of contacts per person perday (10–19 persons) | 0.879 | 1.057 | 0.516 | 2.167 | 0.305 | 2.115 | 0.506 | 8.846 |
Average number of contacts per person perday (20–49 persons) | 0.903 | 1.046 | 0.513 | 2.132 | 0.228 | 2.404 | 0.578 | 9.995 |
Average number of contacts per person perday (50–100 persons) | 0.522 | 0.778 | 0.362 | 1.675 | 0.178 | 2.722 | 0.634 | 11.678 |
Verification of compliance with mandatory quarantine rules (frequently) | 0.786 | 1.045 | 0.761 | 1.435 | 0.976 | 0.993 | 0.633 | 1.559 |
Verification of compliance with mandatory quarantine rules (occasionally) | 0.602 | 1.073 | 0.822 | 1.401 | 0.534 | 1.128 | 0.772 | 1.647 |
Protection of public gatherings > 50 persons (frequently) | 0.261 | 0.780 | 0.505 | 1.204 | 0.815 | 1.070 | 0.605 | 1.893 |
Protection of public gatherings > 50 persons (1–2 times) | 0.391 | 1.135 | 0.850 | 1.514 | 0.815 | 1.052 | 0.690 | 1.602 |
Presence of chronic condition (yes) | 0.750 | 1.035 | 0.837 | 1.281 | 0.479 | 0.897 | 0.664 | 1.212 |
Tobacco smoking (daily) | 0.572 | 1.077 | 0.833 | 1.393 | 0.182 | 0.772 | 0.528 | 1.129 |
Tobacco smoking (occasionally) | 0.393 | 1.137 | 0.846 | 1.528 | 0.113 | 0.684 | 0.427 | 1.094 |
E-cigarette use/vaping (daily) | 0.319 | 0.715 | 0.370 | 1.382 | 0.024 | 2.058 | 1.097 | 3.861 |
E- cigarette use/vaping (occasionally) | 0.465 | 1.225 | 0.710 | 2.114 | 0.455 | 1.349 | 0.616 | 2.952 |
Heated tobacco use (daily) | 0.858 | 1.056 | 0.581 | 1.919 | 0.549 | 0.730 | 0.260 | 2.045 |
Heated tobacco use (occasionally) | 0.844 | 0.941 | 0.511 | 1.732 | 0.088 | 1.870 | 0.911 | 3.838 |
Foreign trip in the first half of 2020 (yes) | 0.625 | 0.841 | 0.420 | 1.685 | 0.335 | 0.565 | 0.177 | 1.804 |
Number of COVID-19 cases in the poviat (administrative region) per 10,000 residents | 0.102 | 1.033 | 0.994 | 1.073 | 0.202 | 1.035 | 0.982 | 1.090 |
Number of COVID-19 related deaths in the poviat (administrative region) per 10,000 residents | 0.589 | 0.897 | 0.604 | 1.331 | 0.506 | 0.833 | 0.486 | 1.428 |
Constant | 0.000 | 0.033 | 0.000 | 0.006 |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gujski, M.; Jankowski, M.; Pinkas, J.; Wierzba, W.; Samel-Kowalik, P.; Zaczyński, A.; Jędrusik, P.; Pańkowski, I.; Juszczyk, G.; Rakocy, K.; et al. Prevalence of Current and Past SARS-CoV-2 Infections among Police Employees in Poland, June–July 2020. J. Clin. Med. 2020, 9, 3245. https://doi.org/10.3390/jcm9103245
Gujski M, Jankowski M, Pinkas J, Wierzba W, Samel-Kowalik P, Zaczyński A, Jędrusik P, Pańkowski I, Juszczyk G, Rakocy K, et al. Prevalence of Current and Past SARS-CoV-2 Infections among Police Employees in Poland, June–July 2020. Journal of Clinical Medicine. 2020; 9(10):3245. https://doi.org/10.3390/jcm9103245
Chicago/Turabian StyleGujski, Mariusz, Mateusz Jankowski, Jarosław Pinkas, Waldemar Wierzba, Piotr Samel-Kowalik, Artur Zaczyński, Piotr Jędrusik, Igor Pańkowski, Grzegorz Juszczyk, Kamil Rakocy, and et al. 2020. "Prevalence of Current and Past SARS-CoV-2 Infections among Police Employees in Poland, June–July 2020" Journal of Clinical Medicine 9, no. 10: 3245. https://doi.org/10.3390/jcm9103245
APA StyleGujski, M., Jankowski, M., Pinkas, J., Wierzba, W., Samel-Kowalik, P., Zaczyński, A., Jędrusik, P., Pańkowski, I., Juszczyk, G., Rakocy, K., & Raciborski, F. (2020). Prevalence of Current and Past SARS-CoV-2 Infections among Police Employees in Poland, June–July 2020. Journal of Clinical Medicine, 9(10), 3245. https://doi.org/10.3390/jcm9103245